JAYPIRCA FILM-COATED TABLETS 100MG [SIN17628P]
Active ingredients: PIRTOBRUTINIB
Product Info
JAYPIRCA FILM-COATED TABLETS 100MG
[SIN17628P]
Product information
Active Ingredient and Strength | PIRTOBRUTINIB - 100 MG |
Dosage Form | TABLET, FILM COATED |
Manufacturer and Country | LILLY DEL CARIBE, INC - UNITED STATES |
Registration Number | SIN17628P |
Licence Holder | DKSH SINGAPORE PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | L01EL05 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
4.1 Therapeutic indications
Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy including a covalent Bruton’s tyrosine kinase (BTK) inhibitor.
Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) who have been previously treated with a covalent BTK inhibitor.
Dosing
4.2 Posology and method of administration
Jaypirca therapy should be initiated and supervised by physicians experienced in the use of anticancer therapies.
Posology
The recommended dose is 200 mg pirtobrutinib once daily (QD).
Jaypirca dosing should be interrupted until recovery to Grade 1 or baseline when the patient experiences the following event:
Grade 3 neutropenia with fever and/or infection
Grade 4 neutropenia lasting ≥ 7 days
Grade 3 thrombocytopenia with bleeding
Grade 4 thrombocytopenia
Grade 3 or 4 non-haematologic toxicity
Asymptomatic lymphocytosis is not regarded as an adverse reaction, and patients experiencing this event should continue taking Jaypirca.
In the clinical studies, adverse events in a limited number of patients were managed by dose reduction (see section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Treatment should be continued until disease progression or unacceptable toxicity.

Missed dose
If more than 12 hours have passed after a patient has missed a dose, the patient should be instructed to take the next dose at its scheduled time; an additional dose should not be taken. If vomiting occurs, the patient should not take an additional dose but continue with the next scheduled dose.
Special populations
Elderly
No dose adjustment is required based on age (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Renal impairment
No dose adjustment is required for patients with mild, moderate or severe renal impairment. There are no data in patients on dialysis (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Hepatic impairment
No dose adjustment is required for patients with mild, moderate, or severe hepatic impairment (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Paediatric population
The safety and efficacy of Jaypirca in children and adolescents aged less than 18 years have not been established. No data are available.
Method of administration
Jaypirca is for oral use.
The tablet should be swallowed whole with a glass of water to ensure consistent performance (patients should not chew, crush, or split tablets before swallowing) and can be taken with or without food. Patients should take the dose at approximately the same time every day.
Contraindications
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
